


# Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis


Jae-Ho Cheong\*, Han-Kwang Yang, Hyunki Kim, Woo Ho Kim, Young-Woo Kim, Myeong-Cherl Kook, Young-Kyu Park, Hyung-Ho Kim, Hye Seung Lee, Kyung Hee Lee, Mi Jin Gu, Ha Yan Kim, Jinae Lee, Seung Ho Choi, Soonwon Hong, Jong Won Kim, Yoon Young Choi, Woo Jin Hyung, Eunji Jang, Hyeseon Kim, Yong-Min Huh, Sung Hoon Noh\*



**Figure 3: Overall survival in the validation cohort by single patient classifiers**  
 625 of the 629 tumour samples from patients in the CLASSIC trial are included in these analyses; four samples were excluded during the RNA quality control evaluation. (A) Overall survival by treatment (D2 gastrectomy plus adjuvant chemotherapy or D2 gastrectomy only). (B) Overall survival by prognostic single patient classifier groups. (C) Overall survival by predictive single patient classifier, chemotherapy-benefit group, and treatment received. (D) Overall survival by predictive single patient classifier, no-benefit group, and treatment received. HR=hazard ratio.

# Mismatch Repair Deficiency, Microsatellite Instability, and Survival

## An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial



patients with MSI-H or MMRD **may not benefit (or may experience a detrimental effect)** from perioperative chemotherapy